How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials.

Mol Psychiatry 2009 Apr 8;14(4):429-47. Epub 2008 Jan 8.

Department of Psychiatry and Psychotherapy, Klinik für Psychiatrie und Psychotherapie der TU-München, Klinikum rechts der Isar, Technische Universität München, München, Germany.

We conducted a systematic review and meta-analysis of randomized controlled trials that compared second-generation antipsychotic (SGA) drugs with placebo in schizophrenic patients and which considered 13 different outcome measures. Thirty-eight randomized controlled trials with 7323 participants were included. All SGA drugs were more effective than placebo, but the pooled effect size (ES) for overall symptoms (primary outcome) was moderate (-0.51). The absolute difference (RD) in responder rates was at 18% (41% responded to drug compared with 24% to placebo, number needed to treat=6). Similar ESs were found for the other efficacy parameters: negative symptoms (ES=-0.39), positive symptoms (ES=-0.48), depression (ES=-0.26), relapse (RD 20%) and discontinuation due to inefficacy (RD 17%). Curiously, the efficacy of haloperidol for negative and depressive symptoms was similar to that of the SGA drugs. In contrast to haloperidol, there was no difference in terms of EPS between any SGA drugs and placebo, and there was also no difference in terms of dropouts due to adverse events. Meta-regression showed a decline in treatment response over time, and a funnel plot suggested the possibility of publication bias. We conclude that the drug versus placebo difference of SGA drugs and haloperidol in recent trials was moderate, and that there is much room for more efficacious compounds. Whether methodological issues account in part for the relatively low efficacy ESs and the scarcity of adverse event differences compared with placebo needs to be established.

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.mp.4002136DOI Listing
April 2009
3 Reads

Publication Analysis

Top Keywords

sga drugs
20
randomized controlled
8
controlled trials
8
difference terms
8
drugs placebo
8
second-generation antipsychotic
8
placebo difference
8
placebo
6
sga
5
drugs
5
haloperidol trials
4
ess efficacy
4
needed treat=6
4
treat=6 ess
4
positive symptoms
4
symptoms es=-039
4
es=-039 positive
4
negative symptoms
4
parameters negative
4
drugs haloperidol
4

References

(Supplied by CrossRef)

P Bentham et al.
Lancet 2004

J Moncrieff et al.
BMJ 2005

CE Adams et al.
2007

JM Davis et al.
Arch Gen Psychiatry 2003

J Geddes et al.
BMJ 2000

JPT Higgins et al.
2005

LA Arvanitis et al.
Biol Psychiatry 1997

SR Kay et al.
Schizophr Bull 1987

JE Overall et al.
Psychol Rep 1962

W Guy et al.
1976

M Simpson et al.
Acta Psychiatr Scand Suppl 1970

Similar Publications